Momentum investing is essentially the opposite of the tried-and-tested Wall Street adage -- "buy low and sell high." Investors following this investing style typically avoid betting on cheap stocks and waiting long for them to recover. They believe instead that one could make far more money in lesser time by "buying high and selling higher."Everyone likes betting on fast-moving trending stocks, but it isn't easy to determine the right entry point. These stocks often lose momentum when their future growth po ...

Accuray Incorporated (ARAY) recently announced that its Radixact SynC System and CyberKnife S7 System have been approved by the Chinese National Medical Products Administration. These approvals are likely to enable medical care teams to provide patients in China with the most advanced Accuray radiation therapy solutions.The CyberKnife S7 System is the latest generation CyberKnife platform, and the introduction of the Radixact SynC System marks the first approval in the country for the ClearRT kVCT imaging a ...

Company Announcements - Accuray Incorporated announced the approval of its Radixact SynC™ System and CyberKnife® S7™ System by the Chinese National Medical Products Administration (NMPA), enabling the provision of advanced radiation therapy solutions in China [9] - The CyberKnife S7 System is the latest generation CyberKnife platform, and the Radixact SynC System marks the first approval in China for ClearRT® kVCT imaging and Synchrony® real-time adaptive delivery technology on the Radixact System [9] Product Innovations - The Radixact SynC System features a helical design that delivers precise radiation doses continuously from multiple 360-degree rotations around the patient, minimizing dose to healthy tissue [4] - ClearRT is a helical kVCT fan-beam integrated imaging solution for the Radixact System, providing diagnostic-like quality CT images for high confidence in patient set-up and registration steps [5] - The CyberKnife S7 System delivers ultra-hypofractionated radiation therapy, completing treatments in 1 to 5 outpatient sessions compared to conventional 30-40 sessions, benefiting patients unable to travel for extended periods [6] - The CyberKnife S7 System is a robotic, non-invasive radiosurgery device capable of treating tumors with sub-millimetric accuracy in as little as 15 minutes, enabling precise radiation treatments for more patients daily [12] Market Strategy and Growth - The company aims to expand patient access in China by offering unique solutions, addressing the significant demand for radiotherapy treatments, with an estimated need for approximately 2,000 systems over the next five years [10] - The Radixact SynC System is the only helical delivery device in China with Synchrony real-time target tracking and correction technology, enhancing precision for tumors affected by bodily processes or patient movement [11] Leadership and Vision - Suzanne Winter, president and CEO of Accuray, expressed enthusiasm about the timing of the approvals, highlighting the introduction of the Tomo C System and the potential to address the needs of the largest market segment in China [3] - The company is dedicated to continuous innovation in radiation therapy for oncology and neuro-radiosurgery, partnering with clinicians to empower patients to return to their lives faster [7]

Accuray Incorporated (ARAY) is well-poised for growth in the coming quarters, courtesy of continued robust demand for its products. The optimism, led by robust international performance in the first quarter of fiscal 2025 and potential in the Radiosurgery Market, is expected to contribute further. However, reimbursement uncertainties and macroeconomic instability are concerning.This Zacks Rank #2 (Buy) company has gained 28.2% in the year-to-date period compared with 1.6% growth of the industry. The S&P 500 ...

The wait for real acceleration in revenue at Accuray (NASDAQ: ARAY ) increasingly feels like Waiting for Godot, as the company has been trying to sell investors on the China opportunity for years, and yet material revenue accelerationAnalyst’s Disclosure: I/we have a beneficial long position in the shares of ARAY either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). ...

Momentum investing is essentially the opposite of the tried-and-tested Wall Street adage -- "buy low and sell high." Investors following this investing style typically avoid betting on cheap stocks and waiting long for them to recover. They believe instead that one could make far more money in lesser time by "buying high and selling higher."Who doesn't like betting on fast-moving trending stocks? But determining the right entry point isn't easy. Often, these stocks lose momentum once their valuation moves a ...

The MedTech sector faced considerable challenges in 2024, making it a difficult year for investors. In the year, the slow growth of the global economy drew a lot of widespread attention. The year was also marked by significant elections around the world. As per World Economic Forum insights, the U.S. presidential race had an immediate effect on the global economy, with shares hitting record highs and the dollar rising against many currencies. Concerns about the global economic outlook have negatively affect ...

Accuray Incorporated (ARAY) recently revealed findings from an international multicenter analysis, showing that the CyberKnife System delivers effective and time-efficient treatment for brainstem metastases (“BSM”). The study highlights stereotactic radiosurgery (“SRS”) and fractionated stereotactic radiotherapy (“FSRT”) as achievers of long-term local control with a strong safety profile, even in sensitive brain regions.The brainstem is an integral part of the central nervous system and metastatic spread t ...

Study Builds on Extensive Published Literature Highlighting the Benefits of the CyberKnife System in the Treatment of a Wide Range of Neurological Indications MADISON, Wis., Dec. 18, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today an international retrospective multicenter analysis found that radiosurgery (SRS) and fractionated stereotactic radiotherapy (FSRT), delivered with the CyberKnife® System, can provide an effective and time-saving treatment option for brainstem metastases ...

Momentum investing is essentially the opposite of the tried-and-tested Wall Street adage -- "buy low and sell high." Investors following this investing style typically avoid betting on cheap stocks and waiting long for them to recover. They believe instead that one could make far more money in lesser time by "buying high and selling higher."Who doesn't like betting on fast-moving trending stocks? But determining the right entry point isn't easy. Often, these stocks lose momentum once their valuation moves a ...